(BUSINESS WIRE)– Celgene International Sàrl (NASDAQ:CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications:1… Read more »
Shares of Celgene Corporation closed yesterday at $118.27 . CELG has a 1-year high of $123.81 and a 1-year low of $66.85. The stock’s 50-day moving average is $114.26 and it’s 200-day moving average is $98.90.
On the ratings front, Celgene Corporation has been the subject of a number of recent research reports. In a report published on January 13, analyst Mara Goldstein from Cantor Fitzgerald maintained a Buy rating on CELG, with a price target of $131, which implies an upside of 10.8% from current levels. Separately, on January 12, J.P. Morgan`s Cory Kasimov reiterated a Hold rating on Celgene Corporation shares .
In total, one research analyst has assigned a Hold rating and 10 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $118.27 which is 5.4% above where the stock closed yesterday.
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.